Aripiprazole |
| Cariprazine | ||||||
Mania |
|
|
|
| Mania |
|
|
|
Keck et al. (2009); TGA (2009) |
| McIntyre et al. (2009) |
| |||||
| Plac. alone | Lith. alone | Arip. alone |
|
| Plac. alone | Carip. (3 - 12 mg/day) alone |
|
YMRS | n = 163 | n = 154 | n = 153 |
| YMRS | n = 172 | n = 281 |
|
Baseline | 48 | 49 | 48 |
| Baseline | 54 | 53 |
|
3-wk end | 33 | 29 | 26 |
| 3-wk end | 37 | 27 |
|
3-wk change | (−15) | (−20) | (−22) |
| 3-wk change | (−17) | (−26) |
|
Placebo (%) | – | 75 | 68 |
| Placebo (%) | – | 65 |
|
Absolute Advantage (%) | – | +5 | +7 |
| Absolute advantage (%) | – | +9 |
|
Depression |
|
|
|
| Depression |
|
|
|
Fava et al. (2012) |
|
|
| Earley et al. (2019) |
|
| ||
| Plac. + antidep. | Arip. + antidep. |
|
|
| Plac. alone | Carip. (1.5 mg/day) alone | Carip. (3.0 mg/day) alone |
MADRS | N = 54 | N = 167 |
|
| MADRS | N = 141 | N = 145 | N = 164 |
Baseline | 52 | 51 |
|
| Baseline | 50 | 51 | 52 |
4-wk end | 39 | 37 |
|
| 6-wk end | 29 | 26 | 26 |
4-wk change | (−13) | (−14) |
|
| 6-wk change | (−21) | (−25) | (−26) |
Placebo (%) | – | 93 |
|
| Placebo (%) | – | 84 | 81 |
Absolute advantage (%) | – | +1 |
|
| Absolute advantage (%) | – | +4 | +5 |